A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc’s blockbuster multiple sclerosis drug Tecfidera, sending Biogen’s shares down nearly 6%.
https://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.png00Reuters: Health Newshttps://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.pngReuters: Health News2020-06-18 16:06:052020-06-18 16:06:05U.S. district court rules for Mylan in MS drug patent battle with Biogen